Phaseline

Companies › Dren Bio

Dren Bio: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dibotatug (DR-01)
non-fucosylated human IgG1 monoclonal antibody
–Phase 1LGLL - Large Granular Lymphocytic Leukemia; Alopecia Areata; Bone Marrow Failure SyndromesDec 2026
DR-0202
Bispecific antibody
–Phase 1Triple Negative Breast CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05475925Dibotatug (DR-01)Phase 1LGLL - Large Granular Lymphocytic LeukemiaOncologyDec 2026
NCT06602232Dibotatug (DR-01)Phase 1Alopecia AreataImmunologyMay 2027
NCT06999187DR-0202Phase 1Triple Negative Breast CancerOncologyJul 2027
NCT07712562Dibotatug (DR-01)Phase 1Bone Marrow Failure SyndromesHematologyApr 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.